E
Scorpius Holdings, Inc. SCPX
OTC PK
Recommendation
Prev Close
$0.045
Volume
--
Avg Vol (90D)
1,966,816
Market Cap
$219.07K
Dividend & Yield
--
52-Week Range
$0.0301 - $49.20
P/E (TTM)
--
EPS (TTM)
-$101.68
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
4/22/2025 - Globe Newswire
Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives
2/26/2025 - Globe Newswire
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer
1/22/2025 - Globe Newswire
Scorpius Holdings Cancels Planned Reverse Stock Split
1/17/2025 - Globe Newswire
Scorpius Holdings Announces Reverse Stock Split
1/16/2025 - Globe Newswire
Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model
11/19/2024 - Globe Newswire
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
11/14/2024 - Globe Newswire
Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement
11/4/2024 - Globe Newswire
Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually
10/31/2024 - Globe Newswire
Scorpius Holdings Announces Partnership with U.S. Biotech Company
10/22/2024 - Globe Newswire
Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats
10/2/2024 - Globe Newswire
Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
9/30/2024 - Globe Newswire
Scorpius Holdings Commends the U.S. House of Representatives' Passage of the BIOSECURE Act
9/12/2024 - Globe Newswire
Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
9/9/2024 - Globe Newswire
Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow
8/26/2024 - Globe Newswire
Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
8/20/2024 - Globe Newswire
Scorpius Holdings, Inc. Announces Closing of Public Offering
8/19/2024 - Globe Newswire
Scorpius Holdings, Inc. Announces Pricing of Public Offering
8/16/2024 - Globe Newswire
Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering
8/9/2024 - Globe Newswire
Scorpius Holdings Announces Removal of NYSE American Trading Suspension; Expected to Resume Normal Trading on August 2, 2024
7/30/2024 - Globe Newswire
Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter
7/24/2024 - Globe Newswire
Scorpius Holdings Successfully Executes First cGMP Microbial Batches at San Antonio Facility
7/18/2024 - Globe Newswire
Scorpius Holdings Announces Reverse Stock Split
7/17/2024 - Globe Newswire
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
6/17/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$10.04M
EBITDA (TTM)
-$24.13M
EBIT (TTM)
-$31.31M
Net Income (TTM)
-$28.81M
Balance Sheet
Total Assets (Q)
$46.53M
Total Debt (Q)
$14.90M
Total Liabilities (Q)
$21.99M
Book Value Per Share (Q)
$8.12
Cash Flow
Cash from Operations (TTM)
-$21.80M
Cash from Investing (TTM)
$4.93M
Cash from Financing (TTM)
$16.07M
Net Change in Cash (TTM)
-$803.20K
Filings
Filing Date
Thursday, November 14, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Apr 21 and 25 (est)
Price History
Loading...
Beta
-1.66
7-Day Total Return
-67.67%
30-Day Total Return
-72.44%
60-Day Total Return
-84.64%
90-Day Total Return
-85.67%
Year to Date Total Return
-87.55%
1-Year Total Return
-99.87%
2-Year Total Return
-99.97%
3-Year Total Return
-99.99%
5-Year Total Return
-99.99%
52-week Low
Apr 22, 2025 - $0.0301
52-week High
Apr 29, 2024 - $49.20
Valuation
Market Cap
$219.07K - Nano Cap
Enterprise Value
$6.12M
Price/Sales (TTM)
0.03
Price/Book (Q)
0.01
Dividends and Shares
Shares Outstanding
7.06M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.scorpiusbiologics.com
Phone Number
919 240 7133
Address
627 Davis Drive
Morrisville, NC 27560
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and... more